Open AccessNew possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
Author(s) -
Д. С. Касаткин,
Н. В. Хачанова,
В. М. Алифирова,
Alexey Boyko,
K. Z. Bakhtiyarova,
Ya. V. Vlasov,
M. V. Davydovskaya,
Evgeniy Evdoshenko,
С А Сиверцева
Publication year - 2021
Publication title -
nevrologiâ, nejropsihiatriâ, psihosomatika
Language(s) - English
Resource type - Journals
eISSN - 2310-1342
pISSN - 2074-2711
DOI - 10.14412/2074-2711-2021-1-138-144
Subject(s) - multiple sclerosis , clinical practice , medicine , neurology , neurodegeneration , physical therapy , psychiatry , disease
The process of neurodegeneration in multiple sclerosis (MS) remains an urgent problem of modern neurology; from the point of view of its therapy, it is especially important to identify this condition during the transition to secondary progression. This paper reflects the opinion of the Council of Leading MS Experts on the early detection of secondary progressive MS and its diagnostic tools, including the use of new online questionnaires. Special attention is paid to the concept of clinical progression verification using the indicator of the confirmed progression of disability and to the prospect for introducing siponimod (Kiendra® ) into clinical practice for the treatment of patients with secondary progressive MS.